IDEAYA Biosciences Virtual Fireside Chat Hosted by Evercore ISI Transcript
Portions of this transcript marked (technical difficulty) indicate audio problems. The missing text will be supplied if a replay becomes available.
I would see next is a portfolio of assets in the ADC space. I would say probably most attention is to our DLL3 (inaudible). We are guiding towards a clinical data update on that program by the end of the year. And we believe this molecule does have the potential to be a best-in-class asset as both you Umer and John now, we did present a very robust single-agent activity as an oral presentation at the (inaudible) long conference last September. Beyond that, we also have a deep pipeline in MTAP deletion.
We have 2 clinical assets here, both PRMT5 and MAT2A. We think a lot of interesting opportunities, both as monotherapy as well as combination. Also, as I think both of you have been following a lot of interesting intersections between RAS and MTAP as well. And then lastly, CAT6/7. So IDE574 has now entered Phase I. We think a
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
